A triterpenoid derivative, its preparation method, and its application as an HMGCS1 inhibitor
By designing and synthesizing triterpenoid derivatives, the lack of selective modification and active probes for HMGCS1 in existing technologies has been solved, achieving highly selective HMGCS1 inhibition and activity monitoring, with significant inhibitory activity and potential for cell-targeted therapy.
Patent Information
- Application Number
- CN202611331012.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-28
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies lack small molecule compounds that can selectively modify the key catalytic cysteine residue Cys129 of HMGCS1, and also lack HMGCS1 activity probes that can be used for cell and in vivo studies.
A triterpenoid derivative with specific structure and functional groups was designed and synthesized. It can covalently modify Cys129 of HMGCS1 with high selectivity and introduce an alkyne tag for use as an active probe. The synthetic route is shown in Figure 1.
It significantly improved the inhibitory activity against HMGCS1 to the nanomolar level, demonstrating potential for drug development. It also showed the ability to selectively kill tumor cells that highly express HMGCS1 at the cellular level and can be used for monitoring HMGCS1 activity in living cells.
Smart Images

Figure CN123106809A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of pharmaceutical technology, and in particular to a triterpenoid derivative, its preparation method, and its application as an HMGCS1 inhibitor. Background Technology
[0002] Disruption of cholesterol homeostasis is a significant contributing factor to various metabolic diseases, including atherosclerosis, hyperlipidemia, and cardiovascular disease. The mevalonate pathway is the core pathway of cholesterol biosynthesis, in which hydroxymethylglutaryl-CoA synthase 1 (HMGCS1) catalyzes the condensation of acetyl-CoA and acetoacetyl-CoA to form hydroxymethylglutaryl-CoA (HMG-CoA), which is the first rate-limiting enzyme in this pathway. Regulating the activity of this enzyme is of great significance for the treatment of hypercholesterolemia and related cardiovascular diseases.
[0003] The active site of HMGCS1 contains a key catalytic cysteine residue (Cys129), which is an ideal target for designing covalent inhibitors. However, there is currently a lack of small molecule compounds in the clinical market that can selectively modify Cys129 and have strong inhibitory activity.
[0004] In addition, studying the biological function of HMGCS1 and screening its inhibitors requires specific active probes, and currently there is a lack of HMGCS1 active probes that can be used for cell and in vivo studies. Summary of the Invention
[0005] In view of this, the technical problem to be solved by the present invention is to provide a triterpenoid derivative, a method for preparing the same, and its application as an HMGCS1 inhibitor. The prepared triterpenoid derivative has high HMGCS1 inhibitory activity and can be used as an active probe.
[0006] This invention provides a triterpenoid derivative having the structure shown in Formula I or its stereoisomers and salts: Formula I; Among them, ring A is a 5-6 membered alicyclic group; R1 is selected from halogen, vinyl, ethynyl, epoxyalkyl, alkylsulfonate or p-toluenesulfonate; L is a single bond or an unsubstituted or halogenated straight-chain or branched alkylene group of C1 to C10; Y is O or NR y ;R y It is hydrogen, C1~C6 alkyl, or C2~C6 alkynyl; R2 is selected from hydroxyl groups, propargylglycine residues, amino acid residues, polyether chains, biotin, or fluorescent groups; R3~R8 are independently selected from hydrogen or methyl; R xIt is a C1-C6 alkyl group or a C2-C6 alkenyl group; n is any integer from 0 to 5; m is 0 or 1; X is CH2 or C=O; Indicates a single bond or a double bond.
[0007] Preferably, ring A is cyclopentyl or cyclohexyl.
[0008] L is a single bond or an unsubstituted or halogenated straight-chain or branched alkylene group of C1-C10. When L is a single bond, R1 is directly connected to the carbonyl group of the parent nucleus. Preferably, L is a single bond or an unsubstituted or halogenated straight-chain or branched alkylene group of C1-C6; more preferably, L is a single bond or an unsubstituted or halogenated straight-chain or branched alkylene group of C1-C3; exemplary, L is a single bond, methylene, 1,1-ethylene, or 1,2-ethylene.
[0009] R1 is selected from halogen, vinyl, ethynyl, epoxy alkyl, alkyl sulfonate, or p-toluene sulfonate; the epoxy alkyl is preferably a 3- to 6-membered epoxy alkyl, and for example, it can be propylene oxide, butane oxide, pentane oxide, or hexane oxide; the alkyl sulfonate is preferably a C1- to C10 alkyl sulfonate, more preferably a C1- to C6 alkyl sulfonate, and even more preferably a C1- to C3 alkyl sulfonate, and for example, it can be a methyl sulfonate or ethyl sulfonate.
[0010] In some specific implementations, -L-R1 has any of the following structures: , , , , , , , , , , , , , .
[0011] R2 is selected from hydroxyl groups, propargylglycine residues, amino acid residues, polyether chains, biotin, or fluorescent groups; the residues are groups formed by the amino group of an amino acid after losing a hydrogen atom.
[0012] In some specific implementations, R2 has any of the following structures: , , , .
[0013] R3 to R8 are independently selected from hydrogen or methyl.
[0014] R x It is an alkyl group of C1 to C6 or an alkenyl group of C2 to C6; the alkyl group of C1 to C6 is preferably an alkyl group of C1 to C3, and for example, it can be methyl, ethyl, n-propyl or isopropyl; the alkenyl group of C2 to C6 is preferably an alkenyl group of C2 to C4, and for example, it can be vinyl, 1-propenyl or 2-propenyl.
[0015] n is R x The number of R values is preferably any integer from 0 to 5, more preferably any integer from 0 to 3. For example, it can be 0, 1, 2, or 3. When n is greater than 1, multiple R values... x They can be the same or different.
[0016] m can be 0 or 1. When m is 0, it means that -(C=O)R2 does not exist.
[0017] R y It can be hydrogen, C1~C6 alkyl, or C2~C6 alkynyl; preferably hydrogen, C1~C3 alkyl, or C2~C4 alkynyl. For example, it can be hydrogen, methyl, ethyl, n-propyl, isopropyl, ethynyl, or propynyl.
[0018] In some specific embodiments, the core of the triterpenoid derivative is derived from oleanolic acid, ursolic acid, glycyrrhetinic acid, betulinic acid, or lupeol, and the triterpenoid derivative has any of the following structures: , , , .
[0019] In some specific embodiments, the triterpenoid derivative has any of the following structures: .
[0020] The triterpenoid derivatives provided by this invention can be in the form of stereoisomers, racemic forms, or salts. The salts can be pharmaceutically acceptable salts, including but not limited to sodium salts, potassium salts, ammonium salts, calcium salts, zinc salts, etc.
[0021] This invention provides a method for preparing the above-mentioned triterpenoid derivatives, comprising the following steps: The compound shown in Formula I-a and the compound shown in Formula I-b undergo a first substitution reaction, and then undergo a second substitution reaction with R2H to obtain the triterpenoid derivative shown in Formula I. Formula I-a; Formula I-b; Formula I; Ring A, R1-R8, L, R x m, n, X The definition is the same as above; YH is OH or NH.
[0022] The first substitution reaction described above involves the substitution of a hydroxyl group in the compound shown in Formula I-a with a chlorine atom in the compound shown in Formula I-b, resulting in the loss of one molecule of HCl. The first substitution reaction is preferably carried out in the presence of pyridine. The first substitution reaction is preferably carried out with the addition of a condensing agent, preferably DMAP. The solvent for the first substitution reaction is preferably dichloromethane.
[0023] The intermediate obtained from the first substitution reaction described above has the structure shown in formula I-c: Formula I-c.
[0024] The second substitution reaction described above involves the reaction of the carboxyl group of formula I-c with the amino group of R2H, resulting in the loss of one molecule of H2O. This second substitution reaction is preferably carried out in the presence of a coupling agent and a condensing agent. The coupling agent is preferably HBTU, and the condensing agent is preferably DIEA. The solvent for the second condensation reaction is preferably DMF.
[0025] The present invention provides a pharmaceutical composition comprising the above-mentioned triterpenoid derivative and an excipient.
[0026] The dosage forms of the pharmaceutical composition include, but are not limited to, oral formulations, injections, topical formulations, liposomes, or nanoparticles. Oral formulations include, but are not limited to, tablets, capsules, and granules; injections include, but are not limited to, intravenous injections and intramuscular injections; and topical formulations include, but are not limited to, creams and gels.
[0027] The present invention does not impose any special limitation on the type of excipients, and those skilled in the art can choose pharmaceutically acceptable excipients that are known.
[0028] HMGCS1 is highly expressed in various tumors, but there is a lack of targeted therapy strategies. HMGCS1-mediated cancer cell development is very important for the early diagnosis of cancers such as cervical cancer. Existing tools are difficult to monitor changes in HMGCS1 activity in living cells. The compound provided by this invention can be used as a probe to efficiently monitor HMGCS1 activity in living cells and has a selective killing effect on HeLa cells that highly express HMGCS1, suggesting its anti-tumor potential.
[0029] Furthermore, experimental results show that the covalent derivative based on the oleanolic acid skeleton provided by this invention exhibits high inhibitory activity against HMGCS1 (IC50). 50 (Danamore grade), and selectively labeled Cys129. Natural oleanolic acid IC 50 With a molecular weight of approximately 70 μM, it is difficult to directly formulate into a drug. This invention introduces an electrophilic warhead through structural modification, which significantly enhances its inhibitory activity.
[0030] Based on this, the present invention provides the application of the above-mentioned triterpenoid derivatives in the preparation of HMGCS1 inhibitors.
[0031] Specifically, this invention provides the use of the above-mentioned triterpenoid derivatives in the preparation of cholesterol-lowering drugs, antitumor drugs, anti-inflammatory drugs, antiviral drugs, and drugs for the prevention, treatment, and / or alleviation of metabolic diseases and neurodegenerative diseases.
[0032] The tumors mentioned include, but are not limited to, stomach cancer, colon cancer, cervical cancer, and leukemia.
[0033] The anti-inflammatory drug can target some inflammatory conditions in which HMGCS1 is involved in immune cell metabolism.
[0034] The antiviral drug can target certain viruses that rely on host cholesterol synthesis.
[0035] The metabolic diseases mentioned include, but are not limited to, non-alcoholic fatty liver disease (NAFLD).
[0036] The neurodegenerative diseases mentioned include, but are not limited to, Alzheimer's disease, which is related to cholesterol metabolism.
[0037] Compared with existing technologies, this invention provides a series of triterpenoid derivatives. This invention achieves the following beneficial effects: 1. Significantly enhanced inhibitory activity: Compared with natural products, this invention improves the inhibitory activity of HMGCS1 by more than 100 times by introducing R1 as an electrophilic warhead into the structure, reaching the nanomolar level, which has the potential for drug development, and is more selective, with a novel structure that is easy to optimize. 2. Clearly defined site specificity: This invention achieves precise covalent modification of the HMGCS1 active site Cys129 through structural biology guidance and chemical design. Mutation and competition experiments confirmed its site of action; 3. Excellent cell viability: YC-1 significantly inhibited cholesterol synthesis in HepG2 cells at a concentration of 5 μM without cytotoxicity. The parent compound oleanolic acid was ineffective at the same concentration, indicating that the derivative provided by this invention has better cell permeability and target binding ability. 4. Selective anti-tumor potential: This invention is the first to discover that HMGCS1 inhibitors have a selective killing effect on tumor cells that highly express this enzyme, providing a new approach for tumor treatment that targets cholesterol metabolism; 5. Can be used as an active probe: YC-1 has an alkynyl tag, which can be used in click chemistry, making it a chemical probe for HMGCS1 activity detection, target verification and imaging studies, making up for the lack of such tools in existing technologies. Attached Figure Description
[0038] Figure 1 This is a synthesis route diagram for YC-1 and YC-2; Figure 2 The above image shows the hydrogen NMR spectrum of YC-1 (top image) and the carbon NMR spectrum (bottom image). Figure 3 The above image shows the hydrogen NMR spectrum of YC-2 (top image) and the carbon NMR spectrum (bottom image). Figure 4 This is a graph validating the binding of oleanolic acid (OA) to HMGCS1. In graph a, we show the preference of various drugs for the K273 site of HMGCS1, as verified using SPIDER technology. In graph b, we show the thermostability curves of HMGCS1 treated with LCA and C13, indicating that C13 can bind to HMGCS1 in a similar manner to LCA and improve its thermostability. In graph c, we show the IC50 of C13's inhibitory effect on HMGCS1 enzyme activity. 50 d represents the quantitative determination of the binding ability of C13 to HMGCS1 using the BLI experiment; Figure 5 In the diagram, a shows the molecular docking simulation of YC-1 and HMGCS1; b shows the labeling results of YC-1 to YC-5 on wild-type HMGCS1 and the C129A mutant; c shows the in vitro enzyme activity inhibition curves of YC-1, YC-2, and OA on HMGCS1; d shows the labeling specificity of YC-1 in the proteome; and e shows the labeling specificity of YC-2 in the proteome. Figure 6 Results of the Hymeglusin competition experiment; Figure 7 The study aimed to investigate the effects of YC-1 on the inhibition of newly synthesized cholesterol synthesis in HepG2 cells and the rescue of the YC-1-mediated phenotype by overexpression of HMGCS1. Specifically, a) the effect of different inhibitors on newly synthesized cholesterol was evaluated using a relabeled glucose metabolism marker-based strategy; b) the effects of concentration gradients of YC-1, YC-2, and oleanolic acid on the reduction of newly synthesized cholesterol; and c) the rescue effect of HMGCS1 overexpression on the YC-1-mediated reduction of newly synthesized cholesterol phenotype in HepG2 cells. Figure 8This diagram illustrates how YC-1 induces selective cytotoxicity in different cell lines by targeting HMGCS1. In the diagram, a shows the detection of HMGCS1 activity in different cell lines using YC-1, and b shows that the HeLa cell line, which exhibits stronger HMGCS1 activity, is more sensitive to YC-1 treatment, while the HepG2 cell line, which exhibits weaker HMGCS1 activity, shows better resistance to YC-1. Detailed Implementation
[0039] To further illustrate the present invention, a detailed description is provided below with reference to embodiments. However, it should be understood that these descriptions are merely for further illustrating the features and advantages of the present invention, and not for limiting the scope of the claims.
[0040] There are no particular restrictions on the source of any raw materials used in this invention; they can be purchased from the market or prepared using conventional methods known to those skilled in the art.
[0041] Information on the biological materials used in the following experiments: HMGCS1 expression plasmid: pET28a-HMGCS1, constructed in our laboratory; HeLa cells: ATCC CCL-2; HepG2 cells: ATCC HB-8065; HEK293T cells: ATCC CRL-3216; K562 cells: ATCC CCL-243.
[0042] Example 1: Synthesis of YC-1
[0043] (1) Synthesis of intermediate 1 (oleanolic acid ester): Dissolve 1.0 equivalent of oleanolic acid (C13) in anhydrous dichloromethane; add 3.0 equivalent of pyridine and 0.1 equivalent of DMAP, and stir in an ice bath; slowly add 1.2 equivalent of acryloyl chloride, and the reaction is exothermic and violent; restore to room temperature and stir overnight; quench with 1M hydrochloric acid, wash twice with dilute hydrochloric acid, and wash once with saturated brine; dry with anhydrous sodium sulfate and evaporate to dryness; purify by column chromatography (DCM / 0.1% formic acid) to obtain a white powder product, denoted as intermediate 1, with a yield of 86%.
[0044] (2) Synthesis of YC-1: Take 1.0 equivalent of intermediate 1 and 1.2 equivalent of HBTU, and dissolve them in anhydrous DMF; add 2.0 equivalent of DIEA and 1.5 equivalent of propargylglycine in DMF solution; react overnight at room temperature; dilute with ethyl acetate, wash twice with dilute hydrochloric acid, and wash once with saturated brine; dry with anhydrous sodium sulfate; purify by column chromatography (DCM:MeOH=100:1, containing 0.1% formic acid) to obtain a white powder product YC-1 with a yield of 67%.
[0045] The reaction equation is as follows Figure 1 As shown in the image above.
[0046] Compound characterization: 1 H NMR (500 MHz, CDCl3) 1 H NMR (500 MHz, CDCl3) δ = 8.04 (s, 1H), 6.88 (d, J = 5.6 Hz, 1H), 6.38 (d, J = 17.3 Hz, 1H), 6.12 (dd, J = 17.3, 10.4 Hz,1H), 5.81 (d, J = 11.0 Hz, 1H), 5.46 (s, 1H), 4.56 (dd, J = 15.9, 7.8 Hz,2H), 2.98 (s, 1H), 2.04 (s, 2H), 1.91 (d, J = 7.2 Hz, 2H), 1.77 (t, J = 13.4Hz, 1H), 1.66 (s, 6H), 1.51 (d, J = 8.8 Hz, 1H), 1.46 (d, J = 12.8 Hz, 1H), 1.36 (dd, J = 16.5, 8.7 Hz, 3H), 1.26 (t, J = 12.3 Hz, 4H), 1.17 (s, 3H), 1.08 (t, J = 12.9 Hz, 2H), 0.94 – 0.90 (m, 8H), 0.88 (d, J = 3.7 Hz, 7H), 0.74 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 179.58 (s), 172.15 (s), 166.11 (s), 163.02 (s), 143.61 (s), 130.19 (s), 129.11 (s), 123.58 (s), 81.02 (s), 78.72(s), 71.45 (s), 55.23 (s), 51.18 (s), 47.49 (s), 46.59 (s), 46.40 (s), 41.98(s), 39.47 (s), 38.67 (s), 38.19 (s), 37.88 (s), 36.79 (d, J = 15.0 Hz),34.06 (s), 32.96 (s), 32.53 (d, J = 17.1 Hz), 31.66 (s), 30.73 (s), 28.05 (s), 27.33 (s), 25.69 (s), 23.55 (dd, J = 20.8, 14.9 Hz), 21.37 (s), 18.17(s), 16.75 (s), 16.58 (s), 15.48 (s). HRMS (ESI) m / z: [MH] - calcd forC 38 H 54 N2O5 - 604.4002, found: 604.4010. The proton NMR spectrum and carbon NMR spectrum are as follows: Figure 2 As shown.
[0047] Example 2 Synthesis of YC-2
[0048] (1) Synthesis of intermediate 2 (chloroacetic acid oleanolic acid ester): Dissolve 1.0 equivalent of oleanolic acid in anhydrous dichloromethane; add 3.0 equivalent of pyridine and 0.1 equivalent of DMAP, and stir in an ice bath; slowly add 1.2 equivalent of chloroacetyl chloride; react overnight at room temperature; quench with 1M hydrochloric acid, wash twice with dilute hydrochloric acid, and wash once with saturated brine; dry with anhydrous sodium sulfate and evaporate to dryness; purify by column chromatography to obtain a pale yellow powder, designated as intermediate 2, with a yield of 91%.
[0049] (2) Synthesis of YC-2: Take 1.0 equivalent of intermediate 2 and 1.2 equivalent of HBTU, dissolve in anhydrous DMF; add 2.0 equivalent of DIEA and 1.5 equivalent of propargylglycine in DMF solution; react overnight at room temperature; dilute with ethyl acetate, wash twice with dilute hydrochloric acid, and wash once with saturated brine; dry with anhydrous sodium sulfate; purify by column chromatography to obtain pale yellow powder YC-2, yield 27%.
[0050] The reaction equation is as follows Figure 1 As shown in the image below.
[0051] Compound characterization: 1 H NMR (400 MHz, CDCl3) δ 5.46 (s, 1H), 4.63 – 4.48 (m, 2H), 4.06 (d, J = 1.8 Hz, 2H), 2.93 – 2.73 (m, 2H), 2.64 (d, J = 10.3 Hz, 1H), 2.24 (t, J =7.5 Hz, 1H), 2.11 – 2.00 (m, 3H), 1.90 (d, J = 5.8 Hz, 2H), 1.65 (d, J = 14.0Hz, 6H), 1.56 (dd, J = 22.5, 12.6 Hz, 4H), 1.26 (s, 8H), 1.17 (s, 4H), 0.92(s, 9H), 0.88 (d, J = 6.9 Hz, 7H), 0.74 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ177.97 (s), 167.13 (s), 144.75 (s), 122.98 (s), 83.22 (s), 79.70 (s), 71.59(s), 55.14 (s), 47.45 (s), 46.60 (s), 46.30 (s), 42.05 (d, J = 8.8 Hz), 41.23(s), 39.40 (s), 37.99 (d, J = 19.0 Hz), 36.82 (s), 34.07 (s), 32.98 (s), 32.25 (d, J= 3.8 Hz), 30.72 (s), 29.33 (s), 28.00 (s), 27.23 (s), 25.73 (s), 23.85 (s), 23.82 – 23.17 (m), 18.13 (s), 16.97 (s), 16.61 (s), 15.43 (s).HRMS (ESI) m / z: [MH] - calcd for C 37 H 53 ClNO5 - 626.3612, found: 626.3609. The proton NMR spectrum and carbon NMR spectrum are as follows: Figure 3 As shown.
[0052] Bioactivity Validation
[0053] 1. In vitro enzyme activity inhibition experiment
[0054] (1) Purify HMGCS1 protein to a final concentration of 100 nM; (2) Add different concentrations of the test compound (0-10 μM) and incubate at 25°C for 30 minutes; (3) Add acetyl-CoA and acetoacetyl-CoA (final concentration 60 μM each), and react at 37°C for 30 minutes; (4) The reaction was terminated by adding 130 μL of cold methanol containing formic acid; (5) Centrifuge at 4℃ and 20000g for 5 minutes, and collect the supernatant; (6) Detection of HMG-CoA generation by triple quadrupole mass spectrometry.
[0055] result: oleanolic acid (OA) IC50 of HMGCS1 50 ≈ 70μM; YC-1 IC for HMGCS1 50 = 264 nM; YC-2 IC for HMGCS1 50 = 507 nM; YC-1 showed approximately 265 times greater inhibitory activity than OA.
[0056] 2. Verification of covalently marked sites
[0057] (1) Incubate wild-type HMGCS1 or C129A mutant protein with YC-1; (2) Perform SDS-PAGE gel electrophoresis; (3) The label signal (YC-1 contains an alkyne group and can be linked to a fluorescent azide) is detected by fluorescence scanning.
[0058] result( Figure 4-6 ): YC-1 can efficiently label wild-type HMGCS1, but has no labeling signal for C129A mutants and is highly selective for HMGCS1; Pre-incubation with the known HMGCS1 covalent inhibitor Hymeglusin can eliminate YC-1 labeling in a concentration-dependent manner; Mass spectrometry analysis confirmed that the YC-1 modification site was Cys129.
[0059] 3. Cellular cholesterol synthesis inhibition experiment
[0060] (1) HepG2 cells were seeded in 6-well plates; (2) Add DMSO or different concentrations of YC-1 (0.5-10 μM) and treat for 4 hours; (3) Replace the culture medium with one-³C6-glucose and continue culturing for 24 hours; (4) Extract lipids and analyze the content of newly formed cholesterol by LC-MS.
[0061] result( Figure 7-8 ): Treatment with 5 μM YC-1 significantly inhibited the synthesis of newly synthesized cholesterol (inhibition rate >60%). The inhibition rate of 10μM YC-1 was >80%, and there was no obvious cytotoxicity. Unmodified oleanolic acid (OA) showed no significant inhibition at 10 μM.
[0062] 4. Target-specific replenishment experiment
[0063] (1) HepG2 cells were transfected with HMGCS1 overexpression plasmid or empty vector control; (2) After 4 hours of YC-1 treatment, the synthesis of new cholesterol was detected.
[0064] result: HMGCS1 overexpression can partially rescue YC-1-induced inhibition of cholesterol synthesis; This indicates that the inhibitory effect of YC-1 depends on HMGCS1.
[0065] 5. Selectively kills tumor cells that highly express HMGCS1
[0066] (1) Detect the expression level of HMGCS1 and the activity of Cys129 in different cell lines; (2) Treat HeLa (high expression) and HepG2 (medium expression) cells with different concentrations of YC-1; (3) MTT assay for cell viability.
[0067] result: HeLa cells are significantly more sensitive to YC-1 than HepG2; IC 50 Values: HeLa approximately 2 μM, HepG2 approximately 8 μM; This indicates that YC-1 has the potential to selectively kill tumor cells that highly express HMGCS1.
[0068] Cell viability is good at the effective concentration.
[0069] The above description of the embodiments is only for the purpose of helping to understand the method and core ideas of the present invention. It should be noted that those skilled in the art can make several improvements and modifications to the present invention without departing from the principles of the present invention, and these improvements and modifications also fall within the protection scope of the claims of the present invention.
Claims
1. A triterpenoid derivative having the structure shown in Formula I or its stereoisomers and salts: Formula I; wherein Ring A is a 5-6 membered alicyclic group; L is a single bond or an unsubstituted or halogenated straight-chain or branched alkylene group of C1 to C10; Y is O or NR y ; R1 is selected from halogen, vinyl, ethynyl, epoxyalkyl, alkylsulfonate or p-toluenesulfonate; R2 is selected from hydroxyl groups, propargylglycine residues, amino acid residues, polyether chains, biotin, or fluorescent groups; R3~R8 are independently selected from hydrogen or methyl; R x R is C1-C6alkyl or C2-C6alkenyl; R y is hydrogen, Ci-C6-alkyl, C2-C6-alkynyl; n is any integer from 0 to 5; m is 0 or 1; X is CH2 or C=O; represents a single or double bond.
2. The triterpene derivative according to claim 1, characterized in that, It has any of the following structures: 、 、 、 。 3. The triterpene derivative according to any one of claims 1 to 2, characterized in that, The -L-R1 has any of the following structures: 、 、 、 、 、 、 、 、 、 、 、 、 、 。 4. The triterpene derivative according to any one of claims 1 to 2, characterized in that, R2 has any of the following structures: 、 、 、 。 5. The triterpene derivative according to claim 1, characterized in that, It has any of the following structures: 。 6. A method for preparing the triterpenoid derivative according to any one of claims 1 to 5, comprising the following steps: The compounds shown in Formula I-a and Formula I-b undergo a substitution reaction, and then a substitution reaction is carried out with R2H to obtain the triterpenoid derivatives shown in Formula I. Formula I-a; Formula I-b; Formula I; Ring A, R1-R8, L, R x m, n, X, as in any one of claims 1 to 5; Y is either O or NH.
7. A pharmaceutical composition comprising the triterpenoid derivative and excipient as described in any one of claims 1 to 5.
8. The pharmaceutical composition of claim 7, wherein, The dosage form of the pharmaceutical composition is an oral preparation, an injection, a topical preparation, a liposome, or a nanoparticle preparation.
9. The use of the triterpenoid derivative according to any one of claims 1 to 5 in the preparation of HMGCS1 inhibitors.
10. The use of the triterpenoid derivatives according to any one of claims 1 to 5 in the preparation of cholesterol-lowering drugs, antitumor drugs, anti-inflammatory drugs, antiviral drugs, and drugs for the prevention, treatment and / or relief of metabolic diseases and neurodegenerative diseases.
